Paper Details

  1. Home
  2. Paper Details

Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell-Bearing Mice.

Author: ChoSeong Hyeok, KangHwa Jeong, KangIn-Cheol, KimJeehye, ParkSo-Jung, YooHwa-Seung

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Combining HangAmDan-B1 (HAD-B1) with afatinib effectively inhibited the growth of lung cancer cells with EGFR mutations (L858R/T790M). This combination led to increased apoptosis and cell cycle arrest, along with changes in cell cycle proteins (reduced pERK1/2 and increased p16). In a preclinical model, this combination significantly reduced tumor volume.
Paper Details　
Original Abstract of the Article :
Epidermal growth factor receptor mutation-positive non-small cell lung cancer is cared for mainly by target therapeutics in the clinical treatment at present. We investigated the antitumor effect of HangAmDan-B1 (HAD-B1) combined with afatinib on H1975 (L858R/T790M double mutation) lung cancer cells...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419252/

データ提供：米国国立医学図書館（NLM）

HangAmDan-B1 and Afatinib: A Powerful Combination for Lung Cancer Treatment

This study investigates the [Antitumor effect of HangAmDan-B1 (HAD-B1) in combination with afatinib] on [H1975 lung cancer cells]. The study uses [In vitro and in vivo models] to evaluate [The combined treatment's impact on cancer cell growth and survival]. The researchers discovered that [HAD-B1 significantly enhanced the antitumor activity of afatinib], leading to [Increased apoptosis and cell cycle arrest in H1975 cells]. This finding is significant because [It suggests that HAD-B1 could be a valuable adjunct therapy for treating EGFR mutation-positive non-small cell lung cancer].

A Promising Approach for Lung Cancer Treatment

The study's results show that [Combining HAD-B1 with afatinib offers a potential therapeutic advantage for patients with EGFR mutation-positive lung cancer].

New Hope for Lung Cancer Patients

This research provides a glimmer of hope for patients with lung cancer, offering a potential new treatment strategy that could improve outcomes. Just as a camel adapts to the desert's harsh conditions, we must also be persistent in our search for effective treatments for cancer and other serious diseases.

Dr. Camel's Conclusion

This study showcases the potential of combining traditional medicine with modern therapeutics to create innovative treatment approaches for cancer. It's a reminder that we should embrace a multidisciplinary approach to medicine, drawing upon various sources of knowledge to improve patient outcomes. Just as a camel uses its unique adaptations to thrive in the desert, we must also be open to new ideas and perspectives to advance the field of medicine.
Date :
  1. Date Completed 2019-12-11
  2. Date Revised 2020-03-09
Further Info :

Pubmed ID

30866688

DOI: Digital Object Identifier

PMC6419252

Related Literature

Article Analysis
・Effects of afatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.